COVID-19 positive donor for solid organ transplantation.


Journal

Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886

Informations de publication

Date de publication:
10 2022
Historique:
received: 15 04 2022
revised: 01 06 2022
accepted: 16 06 2022
pubmed: 8 7 2022
medline: 21 9 2022
entrez: 7 7 2022
Statut: ppublish

Résumé

The COVID-19 pandemic has significantly changed organ donation and transplantation worldwide. Since the beginning of the pandemic, the uncertainty regarding the potential route of transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created tremendous pressures on transplantation communities, and international organisations have advised against using organs from deceased donors who have tested positive for SARS-CoV-2. The possibility of SARS-CoV-2 transmission through organ donation has only been reported for lung transplantation; hence, based on current experience, transplantation of non-lung organs from donors with active SARS-CoV-2 infection has been considered possible and safe, at least over short-term follow-up. As the evolving outbreak of SARS-CoV-2 continues, alongside the presence of vaccines and new treatment options, clinicians should consider transplanting organs from deceased donors with active SARS-CoV-2 infection to recipients with limited opportunities for transplantation and those with specific natural or vaccine-induced immunity. This article proffers an expert opinion on the use of organs from deceased donors with resolved or active SARS-CoV-2 infection in the absence of more definitive data and standardised acceptance patterns.

Identifiants

pubmed: 35798131
pii: S0168-8278(22)02919-1
doi: 10.1016/j.jhep.2022.06.021
pmc: PMC9251900
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1198-1204

Informations de copyright

Copyright © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest PAG has the following conflict of interest: Consulting fees from Merck, Sharp & Dohme, Gilead Sciences, Takeda, Shionogi, Allovir; member of speakers bureau for Merck, Sharp & Dohme, Gilead Sciences, Takeda, Atara; MP has no conflicts of interest to declare. Please refer to the accompanying ICMJE disclosure forms for further details.

Références

Am J Transplant. 2021 Aug;21(8):2885-2889
pubmed: 33565705
Transpl Infect Dis. 2021 Oct;23(5):e13727
pubmed: 34612553
Dig Liver Dis. 2021 Oct;53(10):1232-1234
pubmed: 34393073
Infect Control Hosp Epidemiol. 2021 Jun;42(6):659-668
pubmed: 33077007
Am J Transplant. 2020 Jul;20(7):1795-1799
pubmed: 32368850
Am J Transplant. 2020 Jul;20(7):1780-1784
pubmed: 32243677
Transplant Direct. 2022 Jan 13;8(2):e1286
pubmed: 35047665
Transplantation. 2022 Apr 1;106(4):693-695
pubmed: 35238852
Am J Transplant. 2021 Jul;21(7):2600-2604
pubmed: 33621393
Transpl Infect Dis. 2022 Feb;24(1):e13757
pubmed: 34741572
Am J Transplant. 2020 Jul;20(7):1773-1779
pubmed: 32202064
Transpl Infect Dis. 2022 Feb;24(1):e13761
pubmed: 34797031
Am J Transplant. 2020 Jul;20(7):1787-1794
pubmed: 32400087
Am J Transplant. 2020 Jul;20(7):1826-1836
pubmed: 32323460
Transplantation. 2021 Jul 1;105(7):1405-1422
pubmed: 33724248
Am J Transplant. 2021 Nov;21(11):3743-3749
pubmed: 34254424
Lancet Public Health. 2021 Oct;6(10):e709-e719
pubmed: 34474014
Am J Transplant. 2021 Dec;21(12):3919-3925
pubmed: 34467627
Vaccines (Basel). 2022 Jan 09;10(1):
pubmed: 35062756
Curr Transplant Rep. 2021;8(4):281-292
pubmed: 34722116
Wellcome Open Res. 2020 Jul 29;5:181
pubmed: 33283055

Auteurs

Maddalena Peghin (M)

Infectious and Tropical Diseases Unit, Department of Medicine and Surgery, University of Insubria-ASST-Sette Laghi, Varese, Italy.

Paolo Antonio Grossi (PA)

Infectious and Tropical Diseases Unit, Department of Medicine and Surgery, University of Insubria-ASST-Sette Laghi, Varese, Italy. Electronic address: paolo.grossi@uninsubria.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH